Hologic (HOLX) Aandeel Koers
Hologic Koers
In de afgelopen 19 jaar liet Hologic de omzet jaarlijks met 12,2% groeien tot 4,10 Miljard USD. De winst per aandeel is de afgelopen 19 jaar met 12,8% per jaar gegroeid. Bij Hologic is de nettowinstmarge met 13,8% ten opzichte van 33,2% enkele jaren geleden gedaald. Het consensus-koersdoel voor Hologic op 12 maanden bedraagt 77,52 USD, circa 2,0% boven de huidige koers. Van de 23 analisten geven 0 het aandeel een koopadvies — per saldo een Houden-consensus.
Hologic aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Hologic bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Hologic
The main competitors of Hologic Inc in the market include companies like Abbott Laboratories, Thermo Fisher Scientific, and Becton, Dickinson and Company.
The business model of Hologic Inc revolves around providing innovative diagnostic solutions, primarily focused on women's healthcare. Hologic develops and markets a wide range of medical devices and instruments, including imaging systems, surgical products, and molecular diagnostic assays. The company's products are designed to enable healthcare professionals to effectively screen, diagnose, and treat various conditions and diseases. Hologic is renowned for its advanced technologies in breast health, gynecology, and skeletal health, offering solutions that empower early detection and intervention. By constantly pushing the boundaries of medical technology, Hologic Inc remains committed to improving healthcare outcomes for women around the world.
Hologic Inc is primarily active in the healthcare industry, specifically in the field of diagnostic products and medical devices. With a focus on improving women's health, Hologic Inc develops and manufactures a wide range of innovative solutions. Their portfolio includes advanced imaging systems, molecular diagnostic assays, surgical instruments, and women's health screening tests. As a prominent player in the healthcare sector, Hologic Inc constantly strives to provide cutting-edge technologies and solutions to address various medical challenges.
Hologic Inc is a leading global healthcare and diagnostics company. Established in 1985, Hologic has excelled in providing innovative solutions for women's health, with a focus on early detection and treatment of breast and cervical cancers. The company's dedication to research and development has resulted in breakthrough technologies, including the introduction of the first 3D mammography system. Hologic has expanded its portfolio to include diagnostics, surgical and skeletal health, and GYN surgical products. With a strong commitment to advancing healthcare, Hologic Inc continues to make significant contributions to improving patient outcomes and quality of life.
Hologic Inc, a leading healthcare company, has achieved several significant milestones. In recent years, the company has made notable advancements in breast health solutions. They introduced the world's first 3D mammography system, which revolutionized breast cancer detection by providing clearer and more accurate images. Hologic Inc also developed the Genius™ 3D Mammography™ exam, proven to detect breast cancer at an earlier stage compared to 2D mammography alone. Furthermore, the company expanded its portfolio by acquiring Gen-Probe, a molecular diagnostics company, allowing Hologic Inc to offer a comprehensive range of diagnostic solutions. These milestones highlight Hologic Inc's commitment to innovation and improving women's healthcare outcomes.
Hologic Inc is primarily present in various countries and regions worldwide. The company has a significant presence in the United States, where it is headquartered. Additionally, Hologic Inc operates in Europe, including countries like Germany, France, Italy, and the United Kingdom. It also has a presence in Asia, particularly in countries such as China and Japan. Furthermore, Hologic Inc serves customers in Canada and Latin America, with a focus on countries like Mexico and Brazil. Overall, Hologic Inc has a global reach and aims to provide its products and services to diverse markets internationally.
Hologic Inc represents values of innovation, commitment to quality, and patient-centric approach. The corporate philosophy of Hologic Inc revolves around developing cutting-edge medical technologies to improve women's health outcomes. With a focus on providing accurate and reliable diagnostic solutions, Hologic Inc strives to empower healthcare professionals and patients alike. The company's dedication to research and development, evidence-based practices, and collaboration with healthcare experts reinforces its commitment to advancing healthcare for women globally. Hologic Inc's mission is to make a difference in people's lives through advanced healthcare solutions, making them a trusted and reliable leader in the industry.
Analisten hanteren momenteel een gemiddeld koersdoel van 76,66 USD voor het aandeel Hologic (mediaan: 77,52 USD), oftewel +0,9 % ten opzichte van de laatste koers. De consensus is gebaseerd op 23 analistenratings.
23 analisten beoordelen het aandeel Hologic momenteel: 0 adviseren kopen, 20 houden en 3 verkopen. Voor 2026 verwachten analisten dat Hologic een omzet van 4,24 Miljard USD en winst per aandeel van 4,49 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Hologic op 68,20 EUR (76,01 USD).
Het aandeel Hologic (HOLX) is genoteerd aan 9 beurzen, waaronder: NASDAQ (HOLX), London (0J5Q.L), SIX (Zürich) (HO1.SW), XETRA (HO1.DE), Frankfurt (HO1.F), München (HO1.MU), Düsseldorf (HO1.DU), Wien (HOLX.VI).
Hologic Inc is an international leading provider of medical technology products and solutions. The company, headquartered in Marlborough, Massachusetts, operates globally and is divided into four business segments: Diagnostics, Gynecology, Skeletal Health, and Aesthetics.
De verwachte omzet van Hologic bedraagt 4,24 Miljard USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Hologic bedraagt 1,01 Miljard USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Hologic bedraagt momenteel 16,93. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Hologic-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Hologic bedraagt momenteel 4,05. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Hologic-aandeel.
De Eulerpool Kwaliteitsscore voor Hologic is 1/10.
De ISIN van Hologic is US4364401012. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Hologic is 879100. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Hologic is HOLX. Onder dit beurstickersymbool wordt het Hologic-aandeel op de beurs verhandeld.
Hologic aandeel
Hologic Peer Group
Hologic Ticker
Hologic FIGI
Alle fundamentals en diepgaande analyse van Hologic
Onze aandelenanalyse van het Hologic-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Hologic. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: